Citation: Hanne Trap Wolf, Hanne Kristine Hegaard, Anja Bisgaard Pinborg, Lene Drasbek Huusom. Does Antenatal Administration of Magnesium Sulphate Prevent Cerebral Palsy and Mortality in Preterm Infants? A Study Protocol.[J]. AIMS Public Health, 2015, 3(4): 727-729. doi: 10.3934/publichealth.2015.4.727
| [1] | John P. Elliott, John C. Morrison, James A. Bofill . Risks and Benefits of Magnesium Sulfate Tocolysis in Preterm Labor (PTL). AIMS Public Health, 2016, 3(2): 348-356. doi: 10.3934/publichealth.2016.2.348 |
| [2] | Susanne Klawetter, Jennifer C. Greenfield, Stephanie Rachel Speer, Kyria Brown, Sunah S. Hwang . An integrative review: maternal engagement in the neonatal intensive care unit and health outcomes for U.S.-born preterm infants and their parents. AIMS Public Health, 2019, 6(2): 160-183. doi: 10.3934/publichealth.2019.2.160 |
| [3] | Yelena Ogneva-Himmelberger, Tyler Dahlberg, Kristen Kelly, Tiffany A. Moore Simas . Using Geographic Information Science to Explore Associations between Air Pollution, Environmental Amenities, and Preterm Births. AIMS Public Health, 2015, 2(3): 469-486. doi: 10.3934/publichealth.2015.3.469 |
| [4] | Henry V. Doctor . Assessing Antenatal Care and Newborn Survival in Sub-Saharan Africa within the Context of Renewed Commitments to Save Newborn Lives. AIMS Public Health, 2016, 3(3): 432-447. doi: 10.3934/publichealth.2016.3.432 |
| [5] | Jürgen Vormann . Magnesium: Nutrition and Homoeostasis. AIMS Public Health, 2016, 3(2): 329-340. doi: 10.3934/publichealth.2016.2.329 |
| [6] | Junji Takaya . Small for Gestational Age and Magnesium: Intrauterine magnesium deficiency may induce metabolic syndrome in later life. AIMS Public Health, 2015, 2(4): 793-803. doi: 10.3934/publichealth.2015.4.793 |
| [7] | Sheikh Mohd Saleem, Sudip Bhattacharya . Reducing the infectious diseases burden through “life course approach vaccination” in India—a perspective. AIMS Public Health, 2021, 8(3): 553-562. doi: 10.3934/publichealth.2021045 |
| [8] | Helga Hallgrimsdottir, Leah Shumka, Catherine Althaus, Cecilia Benoit . Fear, Risk, and the Responsible Choice: Risk Narratives and Lowering the Rate of Caesarean Sections in High-income Countries. AIMS Public Health, 2017, 4(6): 615-632. doi: 10.3934/publichealth.2017.6.615 |
| [9] | Sadia Minhas, Rabia Mushtaq Chaudhry, Aneequa Sajjad, Iram Manzoor, Atika Masood, Muhammad Kashif . Corona pandemic: awareness of health care providers in Pakistan. AIMS Public Health, 2020, 7(3): 548-561. doi: 10.3934/publichealth.2020044 |
| [10] | Ying Li, Yilin Chen, Xiwen Ding, Yin Chen, Wei Jiang . Association between sense of control and all-cause mortality: a prospective cohort study. AIMS Public Health, 2025, 12(2): 360-377. doi: 10.3934/publichealth.2025021 |
The risk of cerebral palsy (CP) is inversely correlated with gestational age at birth [1]. CP is accompanied with life-long consequences for the child, its family and society as a whole.Meta-analyses haveindicated that magnesium sulphate may be neuroprotective for the preterm infant, when the drug is given to women at high risk of preterm birth [2,3]. However, this was recently questioned by a trial sequential analysis (TSA), a statistical method which adjusts for risk of random errors [4]. The TSA demonstrated that additional data are needed before accepting magnesium sulphateas evidence-based therapy for women in preterm labour.
Our aim is toinvestigate if antenatal magnesium sulphate administrated to women at risk of preterm birth can protect their children against CP.
This trial is ongoing and is performed as a double-blinded, randomized, controlled, multicenter clinical trial. A study population consisting of 500 women, who are at risk of preterm birth at 24 to 32 weeks of gestation, are randomized to receive either intravenous magnesium sulphate or placebo with saline. The women are recruited from 14 obstetrics departments in Denmark. The children are followed up after 18 months of age by a questionnaire (The Ages & Stages Questionnaire), which is a standardized, validated questionnaire containing questions that can reveal signs of CP [5]. The trial is approved by the Scientific Ethics Committee of the Capital Region of Denmark (H-4-2011-024), the Danish Data Protection Agency (HVH-2011-41-6007) and is registered at ClinicalTrials.gov (no. NCT01492608).
Inclusion criteria are: maternal age ≥ 18 years, gestational age 24+0 to 31+6 weeks, singleton or twin pregnancy, preterm rupture of membranes at 24+0 to 31+6 weeks with contractions and expected birth within 2-24 hours, or preterm contractions and expected birth within 2-24 hours and finally anticipated delivery within 2-24 hours of other reasons (for example fetal growth restriction).
Exclusion criteria are major fetal abnormalities, maternal contraindication to magnesium sulphate (e.g. allergy, myasthenia gravis, kidney failure and heart disease), magnesium sulphate administrated for other reasons (e.g. for prevention of eclampsia) and lack of the ability to understand and speak Danish.
Magnesium sulphate is administrated as a loading dose of five grams infused for 20-30 minutes, followed by a maintenance dose of one gram per hour. Placebo is given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The doses that are used in this project are similar to those used in Denmark for prevention of eclampsia. Blood pressure, pulse rate, respiration rate and reflexes are being controlled throughout the period. Also the fetal heart is monitored closely.
The children are followed up after 18 months of age. A questionnaire will be sent to the parents. If signs of CP are revealed from the questionnaire, the children will be examined neurologically by a pediatrician. The effect will be assessed blinded to the treatment.
A total sample size of 500 patients would allow us to detect or reject a difference in CP of 25% or more with a 5% type 1 error risk. The present trial will with a power of only 13%, not in itself have the power to detect a significant difference between magnesium and placebo treatment. Instead, when the trial is completed, the results will be added to the existing data in a cumulative meta-analysis, in order to ‘close the gap of evidence’ in a TSA, and determine whether magnesium sulphate has an effect. The power of the new meta-analysis will be 63%. We used a one-sided test as a harmful effect of magnesium sulphate on CP seems unlikely according to previous data.
To date more than 380 women have been included in the trial. We expect the inclusion period to end in December 2016. Positive results of this trial will support a change of the clinical guidelines concerning the treatment of women with threatening preterm birth.
No conflict of interests.
| [1] | Himpens E, Van den Broeck C, Oostra A et al. Prevalence, type, distribution, and severity of cerebral palsy in relation to gestational age: a meta-analytic review. Dev Med Child Neurol. May 2008;50(5):334-40. |
| [2] | Wolf HT, Hegaard HK, Greisen G et al. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies. J Obstet Gynaecol J Inst Obstet Gynaecol. February 2012;32(2):135-40. |
| [3] | Doyle LW, Crowther CA, Middleton P et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 2009;(1):CD004661. |
| [4] | Huusom LD, Secher NJ, Pryds O et al. Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants-but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysis. BJOG Int J Obstet Gynaecol. January 2011;118(1):1-5. |
| [5] | Schonhaut L, Armijo I, Schönstedt M et al. Validity of the ages and stages questionnaires in term and preterm infants. Pediatrics. May 2013;131(5):e1468-1474. |
| 1. | Lene Drasbek Huusom, Hanne Trap Wolf, Antenatal magnesium sulfate treatment for women at risk of preterm birth is safe and might decrease the risk of cerebral palsy, 2018, 23, 2515-446X, 195, 10.1136/bmjebm-2018-110897 | |
| 2. | Caroline A. Crowther, Philippa F. Middleton, Merryn Voysey, Lisa Askie, Lelia Duley, Peter G. Pryde, Stéphane Marret, Lex W. Doyle, Jenny E Myers, Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis, 2017, 14, 1549-1676, e1002398, 10.1371/journal.pmed.1002398 | |
| 3. | Clément Chollat, Loïc Sentilhes, Stéphane Marret, Fetal Neuroprotection by Magnesium Sulfate: From Translational Research to Clinical Application, 2018, 9, 1664-2295, 10.3389/fneur.2018.00247 | |
| 4. | H T Wolf, L Huusom, T Weber, A Piedvache, S Schmidt, M Norman, J Zeitlin, Use of magnesium sulfate before 32 weeks of gestation: a European population-based cohort study, 2017, 7, 2044-6055, e013952, 10.1136/bmjopen-2016-013952 |
Hanne Trap Wolf, Hanne Kristine Hegaard, Anja Bisgaard Pinborg, Lene Drasbek Huusom. Does Antenatal Administration of Magnesium Sulphate Prevent Cerebral Palsy and Mortality in Preterm Infants? A Study Protocol.[J]. AIMS Public Health, 2015, 3(4): 727-729. doi: 10.3934/publichealth.2015.4.727
DownLoad: